<p><span style="font-size: small;">Cas [50-56-6]</span><br /><span style="font-size: small;">DEFINITION</span><br /><span style="font-size: small;">L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutamyl-L-asparaginyl-Lcysteinyl-L-prolyl-L-leucylglycinamide cyclic (1→6)-disulfide.</span><br /><span style="font-size: small;">Synthetic cyclic nonapeptide having the structure of thehormone produced by the posterior lobe of the pituitary glandthat stimulates contraction of the uterus and milk ejection inreceptive mammals. It is available in the freeze-dried formas an acetate.</span><br /><span style="font-size: small;">Content: 93.0 per cent to 102.0 per cent (anhydrous and aceticacid-free substance).By convention, for the purpose of labelling oxytocinpreparations, 1 mg of oxytocin peptide (C43H66N12O12S2) isequivalent to 600 IU of biological activity.</span><br /><span style="font-size: small;">CHARACTERS</span><br /><span style="font-size: small;">Appearance: white or almost white, hygroscopic powder.</span><br /><span style="font-size: small;">Solubility: very soluble in water. It dissolves in dilute solutionsof acetic acid and of ethanol (96 per cent).</span><br /><span style="font-size: small;">IDENTIFICATION</span><br /><span style="font-size: small;">A. Examine the chromatograms obtained in the assay.</span><br /><span style="font-size: small;">Results: the principal peak in the chromatogram obtainedwith the test solution is similar in retention time to the principal peak in the chromatogram obtained with the reference solution.</span><br /><span style="font-size: small;">B. Amino acid analysis (2.2.56). For hydrolysis use Method 1 and for analysis use Method 1.</span><br /><span style="font-size: small;">Express the content of each amino acid in moles. Calculate the relative proportions of the amino acids, taking 1/6 of the sum of the number of moles of aspartic acid, glutamic acid, proline, glycine, isoleucine and leucine as equal to 1.The values fall within the following limits: aspartic acid: 0.90 to 1.10; glutamic acid: 0.90 to 1.10; proline: 0.90 to1.10; glycine: 0.90 to 1.10; leucine: 0.90 to 1.10; isoleucine:0.90 to 1.10; tyrosine: 0.7 to 1.05; half-cystine: 1.4 to 2.1. Not more than traces of other amino acids are present.</span><br /><span style="font-size: small;">TESTS</span><br /><span style="font-size: small;">pH (2.2.3): 3.0 to 6.0.</span><br /><span style="font-size: small;">Dissolve 0.200 g in carbon dioxide-free water R and dilute to</span><br /><span style="font-size: small;">10.0 mL with the same solvent.</span><br /><span style="font-size: small;">Related substances. Liquid chromatography (2.2.29): use the</span><br /><span style="font-size: small;">normalisation procedure.</span><br /><span style="font-size: small;">Test solution. Prepare a 0.25mg/mL solution of the substance</span><br /><span style="font-size: small;">to be examined in a 15.6 g/L solution of sodium dihydrogen</span><br /><span style="font-size: small;">phosphate R.</span><br /><span style="font-size: small;">Resolution solution. Dissolve the contents of a vial of</span><br /><span style="font-size: small;">oxytocin/desmopressin validation mixture CRS in 1 mL of a</span><br /><span style="font-size: small;">15.6 g/L solution of sodium dihydrogen phosphate R.</span><br /><span style="font-size: small;">Column:</span><br /><span style="font-size: small;">– size: l = 0.125 m, ? = 4.6 mm;</span><br /><span style="font-size: small;">– stationary phase: octadecylsilyl silica gel for</span><br /><span style="font-size: small;">chromatography R (5 μm).</span><br /><span style="font-size: small;">Mobile phase:</span><br /><span style="font-size: small;">– mobile phase A: 15.6 g/L solution of sodium dihydrogen</span><br /><span style="font-size: small;">phosphate R;</span><br /><span style="font-size: small;">– mobile phase B: acetonitrile for chromatography R, water R</span><br /><span style="font-size: small;">(50:50 V/V);</span><br /><span style="font-size: small;">Time(min)</span><br /><span style="font-size: small;">Mobile phase A</span><br /><span style="font-size: small;">(per cent V/V)</span><br /><span style="font-size: small;">Mobile phase B</span><br /><span style="font-size: small;">(per cent V/V)</span><br /><span style="font-size: small;">0 - 30 70 → 40 30 → 60</span><br /><span style="font-size: small;">30 - 30.1 40 → 70 60 → 30</span><br /><span style="font-size: small;">30.1 - 45 70 30</span><br /><span style="font-size: small;">Flow rate: 1 mL/min.</span><br /><span style="font-size: small;">Detection: spectrophotometer at 220 nm.</span><br /><span style="font-size: small;">Injection: 50 μL.</span><br /><span style="font-size: small;">Retention time: oxytocin = about 7.5 min; desmopressin</span><br /><span style="font-size: small;">= about 10min.</span><br /><span style="font-size: small;">– resolution: minimum 5.0 between the peaks due to</span><br /><span style="font-size: small;">desmopressin and oxytocin.</span><br /><span style="font-size: small;">Limits:</span><br /><span style="font-size: small;">– any impurity: maximum 1.5 per cent;</span><br /><span style="font-size: small;">– total: maximum5 per cent;</span><br /><span style="font-size: small;">– disregard limit: 0.1 per cent.</span><br /><span style="font-size: small;">Acetic acid (2.5.34): 6.0 per cent to 10.0 per cent.</span><br /><span style="font-size: small;">Test solution. Dissolve 15.0 mg of the substance to be</span><br /><span style="font-size: small;">examined in a mixture of 5 volumes of mobile phase B and</span><br /><span style="font-size: small;">95 volumes of mobile phase A and dilute to 10.0 mL with the</span><br /><span style="font-size: small;">same mixture of mobile phases.</span><br /><span style="font-size: small;">Water (2.5.12): maximum 5.0 per cent, determined on at least</span><br /><span style="font-size: small;">50 mg.</span><br /><span style="font-size: small;">Bacterial endotoxins (2.6.14): less than 300 IU/mg, if</span><br /><span style="font-size: small;">intended for use in the manufacture of parenteral preparations</span><br /><span style="font-size: small;">without a further appropriate procedure for removal of</span><br /><span style="font-size: small;">bacterial endotoxins.</span><br /><span style="font-size: small;">ASSAY</span><br /><span style="font-size: small;">Liquid chromatography (2.2.29) as described in the test for</span><br /><span style="font-size: small;">related substances with the following modifications.</span><br /><span style="font-size: small;">Reference solution. Dissolve the contents of a vial of</span><br /><span style="font-size: small;">oxytocin CRS in a 15.6 g/L solution of sodium dihydrogen</span><br /><span style="font-size: small;">phosphate R to obtain a concentration of 0.25 mg/mL.</span><br /><span style="font-size: small;">Injection: 25 μL.</span><br /><span style="font-size: small;">Calculate the content of oxytocin (C43H66N12O12S2) from the</span><br /><span style="font-size: small;">declared content of C43H66N12O12S2 in oxytocin CRS.</span><br /><span style="font-size: small;">STORAGE</span><br /><span style="font-size: small;">In an airtight container, protected from light, at a temperature</span><br /><span style="font-size: small;">of 2 °C to 8 °C. If the substance is sterile, store in a sterile,</span><br /><span style="font-size: small;">airtight, tamper-proof container.</span><br /><span style="font-size: small;">LABELLING</span><br /><span style="font-size: small;">The label states the oxytocin peptide content (C43H66N12O12S2).</span></p>
<p> </p>